Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07081607

Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

In decades, the outcome of patients with peripherial T-cell lymphomas is dismal, especially in relapsed or refractory population. After failure to the frontline treatment, patients have limited treatment options and elderly population usually have no chance to undergo transplantation due to age or comorbidity, etc. Golidocitinib and chidamide were approved in treating r/r PTCL in China, while azacytidine has been demonstrated its anti-tumor activity in PTCL as well.

This study aims to explore the efficacy and safety of golidocitinib combined with azacytidine and chidamide in the patients with peripheral T-cell lymphoma who are eligible for intensive chemotherapy or transplantation.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Peripheral T-Cell Lymphoma, Not Classified Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, Non-Hodgkin Lymphoma, T-Cell Lymphoma, T-Cell, Peripheral Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathologically confirmed peripheral T-cell lymphoma;
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2;
  • Expected survival of ≥12 weeks;
  • Measurable disease lesions;
  • Any conditions considered ineligible for intenvive chemotherapy, including but not limted to age > 60 years, at least one comorbidity scored 3 points, or more than 4 comorbidities scored 2 points each according to the CIRS scale;
  • Female participants of childbearing potential and male participants with partners of childbearing potential must agree to and adhere to effective contraceptive measures during the treatment period and for 180 days after the last dose of the study drug;
  • Participants must voluntarily join the study, sign the informed consent form, demonstrate good compliance, and cooperate with follow-up assessments.

Exclusion criteria

  • Involvement of the central nervous system (CNS);
  • History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix;
  • Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases
  • Left ventricular ejection fraction<50%
  • Laboratory measures meet the following criteria at screening (unless caused by lymphoma):
  • Neutrophils<1.5×10^9/L
  • Platelets<75×10^9/L (Platelets<50×10^9/L in case of bone marrow involvement)
  • ALT or AST is 2 times higher than the upper limits of normal (ULN), AKP and bilirubin are 1.5 times higher than the ULN.
  • Creatinine is 1.5 times higher than the ULN.
  • HIV-infected patients
  • Patients with psychiatric disorders or patients who are known or suspected to be unable to fully comply with the study protocol
  • Pregnant or lactation
  • Require treatment with strong/moderate CYP3A inhibitors or inducers.
  • Inability to swallow capsules or presence of diseases that significantly affect gastrointestinal function, such as malabsorption syndrome, post-bariatric surgery, inflammatory bowel disease and complete or incomplete intestinal obstruction
  • Other medical conditions determined by the researchers that may affect the study

Treatment and study plan

golidocitinib with azacytidine and chidamide

Drug

In Phase I, a "3+3" dose-escalation design will be adopted to enroll 3 to 12 participants, exploring the recommended Phase II dose (RP2D) at two dose levels of golidocitinib: 150 mg every other day (QOD) and 150 mg once daily (QD).

In Phase II, we aim to evaluate the efficacy and safety of golidocitinib RP2D po in combination with chidamide 20mg biw po and azacytidine 100mg d1-7, SC in patients with peripheral T-cell lymphoma

Primary outcomes

  1. Overall Response Rate

    Time frame: Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year

    Percentage of participants with complete response or partial response was determined on the basis of investigator assessments according to 2014 Lugano criteria

Secondary outcomes

  1. Progression-free survival

    Time frame: Baseline up to data cut-off(up to approximately 3 years)

    Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.

  2. Complete Response Rate

    Time frame: Tumor evaluation was assessed at screening and at the end of treatment (around 3 cycles) then every 12-24 weeks until disease progression (each cycle is 21 days) through study completion, an average of 1 year.

    Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.

  3. Duration of Response

    Time frame: Baseline up to data cut-off(up to approximately 3 years)

    Applicable to complete or partial response participants. DoR was defined as the time from the first documented date of complete or partial response until the date of the disease progression or death from any causes.

  4. Overall survival

    Time frame: Baseline up to data cut-off(up to approximately 3 years)

    Overall survival was defined as the time from the date of enrollment to the date of death from any cause.

  5. Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0

    Time frame: From enrollment to study completion, a maximum of 4 years

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Study contacts

Contact information is provided by the study sponsor or research team.

Wang Li

CONTACT

[email protected]

+86 02164370045

Sponsors and collaborators

Lead sponsor

Ruijin Hospital

Other

Registry information

Official study title

An Open-label, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib Combined With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma.

Important dates

Study start
2025
Primary completion
2026
Study completion
2028
First posted
Jul 23, 2025
Registry last updated
Jul 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.